informacje dla lekarzy

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-153. [errata, N. Engl. J. Med. 2000; 342: 748.]
2. Bruce Neal, Stephen MacMahon on behalf of the PROGRESS Management Committee. The PROGRESS study: rationale and design. J. Hypertens. 1995; 13: 1869-1873.
3. Chalmers J., MacMahon S. XI Kongres ESH Mediolan 16.06.2001.
4. Fox K.M. i wsp. The European Trial in Reduction of Cardiac Events with Peryndopryl in Stable Coronary Artery Disease (EUROPA). Eur. Heart J. 1998; 19 (supl. J): J52-J55.
5. European Stroke Initiative Recommendations for Stroke Management. Cerebrovascular Disorders 2000; (supl. 3): 1-33.
6. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905-915.
7. SHEP Cooperative Research Group. Prevention of various stroke types by treatment of isolated systolic hypertension. Presented at: International Stroke Society 2nd World Congress of Stroke; Washington DC; September 1992.